Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
GEM05 for Patients With Multiple Myeloma Under 65 Years
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
† Study has passed its completion date and status has not been verified in more than two years.